<div id="readability-page-1"><p><span>Relay Therapeutics (NASDAQ:RLAY - Get Free Report)</span> had its price objective raised by stock analysts at Citizens Jmp  from $19.00 to $21.00 in a report issued on Wednesday,Benzinga reports. The firm currently has a &#34;market outperform&#34; rating on the stock. Citizens Jmp's price target would suggest a potential upside of 73.99% from the stock's previous close.</p><div><p><span></span><span>Get <strong>Relay Therapeutics</strong> alerts:</span></p></div><ul><li>Unlocking AI investment opportunities in healthcare</li></ul><p>Other equities analysts also recently issued reports about the company. UBS Group  set a $26.00 target price on Relay Therapeutics in a research report on Tuesday. Citigroup  reaffirmed an &#34;outperform&#34; rating on shares of Relay Therapeutics in a research report on Wednesday. HC Wainwright boosted their price target on Relay Therapeutics from $19.00 to $25.00 and gave the company a &#34;buy&#34; rating in a research note on Wednesday, April 29th. Wells Fargo &amp; Company raised their price objective on Relay Therapeutics from $17.00 to $21.00 and gave the stock an &#34;overweight&#34; rating in a research note on Tuesday, April 28th. Finally, Raymond James Financial  reaffirmed a &#34;strong-buy&#34; rating on shares of Relay Therapeutics in a report on Tuesday. One equities research analyst  has rated the stock with a Strong Buy rating, eight have issued  a Buy rating, one  has assigned  a Hold rating and one  has assigned  a Sell rating to the company. Based on data from MarketBeat, the stock currently has a consensus rating of &#34;Moderate Buy&#34; and an average price target of $22.60.</p><p><b>Read Our Latest Research Report on RLAY</b></p><h2>Relay Therapeutics Stock Down 0.2%</h2><p>RLAY stock opened at $12.07 on Wednesday. The firm has a 50 day moving average of $12.56 and a 200 day moving average of $9.62. The stock has a market capitalization of $2.31 billion, a PE ratio of -7.69 and a beta of 1.74. Relay Therapeutics has a 52 week low of $2.75 and a 52 week high of $17.32. </p><p>Relay Therapeutics (NASDAQ:RLAY - Get Free Report) last issued its quarterly earnings results on Tuesday, May 5th. The company reported ($0.41) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.35) by ($0.06). The business had revenue of $3.00 million for the quarter, compared to analyst estimates of $5.58 million.  On average, equities research analysts expect that  Relay Therapeutics will post -1.6 earnings per share for the current year. </p><h2>Insider Transactions at Relay Therapeutics</h2><p>In other Relay Therapeutics news, CFO Thomas Catinazzo sold 17,717 shares of the company's stock in a transaction on Thursday, May 14th. The shares were sold at an average price of $12.86, for a total value of $227,840.62. Following the sale, the chief financial officer directly owned 195,178 shares of the company's stock, valued at approximately $2,509,989.08. This represents a 8.32% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities &amp; Exchange Commission, which can be accessed through this link. Insiders have sold 40,449 shares of company stock worth $532,889 in the last three months. Insiders own  5.04% of the company's stock. </p><h2>Institutional Trading of Relay Therapeutics</h2><p>Hedge funds have recently modified their holdings of the stock. Sanctuary Advisors LLC grew its holdings in  Relay Therapeutics by 1.1% during the first quarter. Sanctuary Advisors LLC now owns 143,816 shares of the company's stock worth $1,431,000 after acquiring an additional 1,588 shares during the period.  Mirae Asset Global Investments Co. Ltd. boosted its position in  Relay Therapeutics by 26.4% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 8,422 shares of the company's stock worth $71,000 after purchasing an additional 1,757 shares in the last quarter.  Abel Hall LLC boosted its position in  Relay Therapeutics by 16.2% in the 4th quarter. Abel Hall LLC now owns 12,984 shares of the company's stock worth $110,000 after purchasing an additional 1,809 shares in the last quarter.  Cresset Asset Management LLC grew its stake in shares of  Relay Therapeutics by 5.0% during the 3rd quarter. Cresset Asset Management LLC now owns 38,932 shares of the company's stock worth $203,000 after purchasing an additional 1,848 shares during the period.  Finally, Vanguard Personalized Indexing Management LLC grew its stake in shares of  Relay Therapeutics by 8.1% during the 3rd quarter. Vanguard Personalized Indexing Management LLC now owns 27,871 shares of the company's stock worth $145,000 after purchasing an additional 2,079 shares during the period. Hedge funds and other institutional investors own  96.98% of the company's stock. </p><h2>Relay Therapeutics News Summary</h2><p>Here are the key news stories impacting Relay Therapeutics this week:</p><ul>   <li><span>Positive Sentiment: </span>Relay Therapeutics’ zovegalisib showed promising early efficacy and tolerability in vascular anomalies, strengthening the case for a broader commercial opportunity. <i></i><span>Article: Relay Therapeutics Announces Initial Clinical Data Demonstrating That Zovegalisib Has Potential for Differentiated Safety and Efficacy in Patients with PIK3CA-Driven Vascular Anomalies</span></li>   <li><span>Positive Sentiment: </span>Raymond James raised its price target on RLAY to $26 and reiterated a strong-buy view, reflecting optimism around the pipeline. <i></i><span>Article: Relay Therapeutics price target raised by Raymond James</span></li>   <li><span>Neutral Sentiment: </span>The company said it has a sizable cash position and runway into 2029, which reduces near-term financing concerns, but this was largely offset by the announced $175 million stock offering. <i></i><span>Article: Relay Therapeutics Announces Proposed Public Offering of Common Stock</span></li>   <li><span>Negative Sentiment: </span>Relay launched a proposed public offering of common stock, which can dilute existing shareholders and pressure the stock in the near term. <i></i><span>Article: Relay Therapeutics Announces Proposed Public Offering of Common Stock</span></li> </ul><h2>About Relay Therapeutics</h2> (Get Free Report)<p>Relay Therapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of precision therapies for oncology. Headquartered in Cambridge, Massachusetts, the company was founded in 2016 with the goal of targeting dynamic protein motion using an integrated scientific platform. Relay Therapeutics leverages computational modeling, structural biology, and experimental validation to identify small-molecule drug candidates that modulate the behavior of disease-associated proteins.  </p><p>The company's core business activity centers on its proprietary drug-discovery engine, which combines high-performance computing—including molecular dynamics simulations—with advanced experimental techniques such as cryo-electron microscopy and biophysical screening.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Relay Therapeutics</li><li>Strategy Inc. Buys Bitcoin and Eyes a Dividend Amid Market Fear</li><li>Vertical Aerospace: Pre-Flight Checks Point to a Breakout</li><li>Palo Alto Networks Up 70%: Can the Rally Last Into June?</li><li>Block’s Pivot to Profits and AI Is Turning Heads</li></ul><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxBWQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" width="650" height="330" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsAndPriceTargetChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9UkxBWQ"/></p><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Relay Therapeutics Right Now?</h2><p>Before you consider Relay Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Relay Therapeutics wasn't on the list.</p><p>While Relay Therapeutics currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

RLAY

SBIO

<p>Citizens Jmp raised the price target for Relay Therapeutics (NASDAQ: RLAY) from $19.00 to $21.00, maintaining a 'market outperform' rating. This suggests a potential upside of 73.99% from the previous close. Other analysts have also set targets ranging from $21.00 to $26.00, with a consensus rating of 'Moderate Buy' and an average price target of $22.60.</p>

Market Beat

Relay Therapeutics

Invesco Biotechnology & Genome ETF

ALPS Medical Breakthrough

VG Health

iShares Biotechnology ETF

VanEck Biotech ETF

Direxion S&P Biotech Bull 3X

iShares Global Healthcare

SPDR S&P Biotech

First Trust NYSE Arca Biotech Index Fd

iShares US Pharma

Ark Genomic Revolution ETF

UBS Group AG

Citigroup

Wells Fargo

Raymond James Financial

CITIGROUP INC 6.250 NON CUM SER II PFD WI

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A DD

WELLS FARGO & COMPANY 7.5% PERP CONV PRF CLS 'A' SERIES 'L'

WELLS FARGO & COMPANY DEP SHS REP 1/1000 INT PER PFD SER Y A

WELLS FARGO & COMPANY DP SHS REP 1/1000TH INT NCUM PFD CL A CC

WELLS FARGO & COMPANY 4.75% DEP SHS 1/1000 NCUM PFD CL A SR Z

WELLS FARGO & COMPANY DEP SHS REP 1/1000TH INT PFD SR AA (CLA)

RAYMOND JAMES FINANCIAL INC 6.375%DEP SHS REP 1/40TH FXD FLTG SER B

Relay Therapeutics (NASDAQ:RLAY) Given New $21.00 Price Target at Citizens Jmp